Supplementary materials: Cost–effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Cost–effectiveness of sotagliflozin for the </b><b>treatment of patients with diabetes and </b><b>recent worsening heart failure</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Supplemental Table 1: </b>Full table of inputs</li><li><b>Supplemental Table 2: </b>Results of scenario analyses</li><li><b>Supplemental Figure 1: </b>Survival curve, sotagliflozin vs. SoC groups</li><li><b>Supplemental Figure 2: </b>Tornado diagram</li></ul><p dir="ltr"><b>Aim:</b> To assesses the cost–effectiveness of sotagliflozin for the treatment of patients hospitalized with heart failure and comorbid diabetes. <b>Materials & methods:</b> A de novo cost–effectiveness model with a Markov structure was created for patients hospitalized for heart failure with comorbid diabetes. Outcomes of interest included hospital readmissions, emergency department visits and all-cause mortality measured over a 30-year time horizon. Baseline event frequencies were derived from published real-world data studies; sotagliflozin’s efficacy was estimated from SOLOIST-WHF. Health benefits were calculated quality-adjusted life years (QALYs). Costs included pharmaceutical costs, rehospitalization, emergency room visits and adverse events. Economic value was measured using the incremental cost–effectiveness ratio (ICER). <b>Results:</b> Sotagliflozin use decreased annualized rehospitalization rates by 34.5% (0.228 vs 0.348, difference: -0.120), annualized emergency department visits by 40.0% (0.091 vs 0.153, difference: -0.061) and annualized mortality by 18.0% (0.298 vs 0.363, difference: -0.065) relative to standard of care, resulting in a net gain in QAYs of 0.425 for sotagliflozin versus standard of care. Incremental costs using sotagliflozin increased by $19,374 over a 30-year time horizon of the patient, driven largely by increased pharmaceutical cost. Estimated ICER for sotagliflozin relative to standard of care was $45,596 per QALY. <b>Conclusion: </b>Sotagliflozin is a cost-effective addition to standard of care for patients hospitalized with heart failure and comorbid diabetes.</p>